Market revenue in 2022 | USD 162.8 million |
Market revenue in 2030 | USD 734.5 million |
Growth rate | 20.7% (CAGR from 2022 to 2030) |
Largest segment | Topo pcr cloning |
Fastest growing segment | Site-Directed Mutagenesis |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Topo PCR Cloning, Blunt End Cloning, Seamless Cloning, Site-Directed Mutagenesis |
Key market players worldwide | Agilent Technologies Inc, Thermo Fisher Scientific Inc, New England Biolabs, Takara Bio Inc, Merck KGaA, Promega, Bio-Rad Laboratories Inc, Danaher Corp, Assay Genie, Jena Bioscience, TransGen Biotech |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cloning and mutagenesis market will help companies and investors design strategic landscapes.
Topo pcr cloning was the largest segment with a revenue share of 29.12% in 2022. Horizon Databook has segmented the Japan cloning and mutagenesis market based on topo pcr cloning, blunt end cloning, seamless cloning, site-directed mutagenesis covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan cloning and mutagenesis market, including forecasts for subscribers. This country databook contains high-level insights into Japan cloning and mutagenesis market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account